Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Marques, T
It might sound strange at first that a diabetes and weight loss drug has the potential to treat addiction disorders, but observations from researchers have led to emerging data, anecdotal reports, and pharmacoepidemiologic findings that suggest GLP-1 drugs could be effective for addiction by reducing drug use and craving through the modulation of reward pathways, stress responses, and cognitive functions
The secondary endpoint of fibrosis reduction by at least one stage was documented in 34%, 36%, and 34% of participants receiving survodutide compared to 22% of placebo, demonstrating potential anti-fibrotic benefit [23]
A systematic review including eight clinical trials and 9424 participants undergoing treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and liraglutide, with obesity but without diabetes resulted in a mean difference of 4.4 mmHg in SBP and a 7.1 kg decrease in body weight [23]
US$ 20.78
US$ 29.88
US$ 24.30
US$ 29.30
